Vertex Pharmaceuticals (NASDAQ:VRTX) Releases Earnings Results, Misses Estimates By $0.06 EPS

Vertex Pharmaceuticals (NASDAQ:VRTX) posted its quarterly earnings results on Monday. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06), FiscalAI reports. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the firm posted $4.80 earnings per share. The firm’s quarterly revenue was up 11.8% on a year-over-year basis.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

• Third-quarter revenue rose 12% year over year, and Vertex raised full-year 2026 revenue guidance to $13.15 billion-$13.25 billion, reflecting continued CF performance and growing contributions from CASGEVY, JOURNAVX, and PALSONIFY.
• Commercial momentum remained strong across newer products: ALYFTREK generated $706 million in quarterly sales, CASGEVY revenue increased 30% sequentially to $99 million, JOURNAVX prescriptions surpassed 750,000, and PALSONIFY reached $10 million in September.
• Vertex is preparing for the November 30 FDA decision on povetacicept in IgA nephropathy, highlighting its expected efficacy, tolerability, and once-monthly at-home auto-injector; the company also completed enrollment in the pivotal AMPLITUDE study of inaxaplin and expects interim data in early 2027.
• The company advanced its pipeline by prioritizing VX-017, an allogeneic, off-the-shelf islet cell therapy for type 1 diabetes, with phase I/II dosing underway and a goal of entering pivotal development next year; it also reported encouraging early results for the VX-828 next-generation CF corrector.
• Vertex increased full-year non-GAAP operating expense guidance to approximately $6 billion, including Crinetics-related costs, and incurred roughly $50 million in third-quarter financing and transaction costs; the Crinetics acquisition also added $4.5 billion in term loans at approximately 4.8% interest.

Vertex Pharmaceuticals Trading Down 1.0%

Vertex Pharmaceuticals stock opened at $553.15 on Tuesday. The company has a market capitalization of $140.39 billion, a P/E ratio of 32.20, a P/E/G ratio of 2.54 and a beta of 0.28. The firm’s fifty day simple moving average is $523.32 and its 200-day simple moving average is $479.96. Vertex Pharmaceuticals has a 1-year low of $403.16 and a 1-year high of $568.67.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, exceeding the $3.42 billion analyst estimate. Growth was supported by continued strength in the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Q3 2026 Earnings Call Transcript
• Positive Sentiment: Vertex raised its full-year 2026 revenue guidance, citing broad-based portfolio growth and the successful completion of its Crinetics Pharmaceuticals acquisition. Management also highlighted its advancing pipeline and a developing nephrology franchise as future growth opportunities. Vertex Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: The transition from Trikafta to newer cystic fibrosis treatment Alyftrek continued to expand the franchise, while the ramp-up of recently launched medicines may diversify Vertex’s long-term revenue base. However, the company is investing heavily in these launches and in the Crinetics deal. Vertex Spends Its CF Growth on New Launches
• Negative Sentiment: Adjusted earnings were $4.76 per share, below analyst expectations of approximately $4.82–$4.92 and down from $4.80 a year earlier. The shortfall reflects increased spending on new product launches, research and development, and the Crinetics acquisition, limiting profit growth despite higher sales. Vertex Misses Q3 Earnings Estimates
• Negative Sentiment: Although full-year revenue guidance was increased, reports characterized the improvement as a light hike that fell short of some investor expectations. That combination—an earnings miss and limited guidance upside—helped pressure the stock despite the revenue beat. Vertex Yo-Yos on Mixed Third-Quarter Report

Analysts Set New Price Targets

VRTX has been the topic of a number of research reports. Daiwa Securities Group upped their target price on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Evercore raised their price target on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the stock an “outperform” rating in a report on Wednesday, September 2nd. UBS Group upped their price objective on shares of Vertex Pharmaceuticals from $585.00 to $615.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Rothschild & Co Redburn increased their target price on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Morgan Stanley initiated coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 1st. They set an “overweight” rating and a $665.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $579.81.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.